While the drug was FDA approved with a broad indication to be used for FLT3 mutant disease, AML presents at an average age 68 and therefore the effects of adding midostauin to standard induction therapy in a population burdened by additional comorbidities has not been well defined. Here, FLT3 is linked to acute myeloid leukemia.